Overview

NCI Definition [1]:
A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.

Cyad-01 has been investigated in 4 clinical trials, of which 2 are open and 2 are closed. Of the trials investigating cyad-01, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for cyad-01 clinical trials.

Myelodysplastic syndromes, acute myeloid leukemia, and breast carcinoma are the most common diseases being investigated in cyad-01 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cyad-01
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cyad-01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cyad-01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous car nkg2d, autologous car-t nkg2d, autologous car-t nkr-2, autologous cm-cs1 t cells, autologous nkg2d car-cd3zeta-dap10-expressing t-cells cyad-01, autologous nkg2d car-cd3zeta-dap10-expressing t-lymphocytes cyad-01, nkr-2, nkr 2, cyad-101, cm-cs1, cm-cs-1, cm cs-1, autologous nkr-2 car-t cells, autologous nkr 2 t-cells, autologous nkg2d car-expressing t-lymphocytes cm-cs1
NCIT ID [1]:
C121536

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.